logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn reveals its drug inhibits colon carcinoma metastases to liver and lung in preclinical study

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive its flagship drug leronlimab inhibited a human colon carcinoma cell line metastases to liver and lung in a well-accepted mouse model.

Pourhassan says the company plans to file an IND for expanded access for a Phase 2 basket trial, including most of the cancer with CCR5 indicators.

Quick facts: CytoDyn Inc.

Price: 0.305 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $118.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn offers update on leronlimab following encouraging...

CytoDyn Inc. (OTCQB:CYDY) CEO Nader Pourhassan and IncellDx Inc CEO Dr Bruce Patterson offer an update on leronlimab's mechanism of action (MOA) in regards to its ongoing cancer trials, specifically in metastatic breast cancer. Dr Patterson says the amazing thing about CCR5 is how it plays...

5 days ago

2 min read